Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

8.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
8.0K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.

Cancer·2019
Same author

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Blood cancer journal·2019
Same author

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Nature communications·2019
Same author

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Clinical lymphoma, myeloma & leukemia·2019
Same author

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.

Journal of hematology & oncology·2019
Same author

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

The Lancet. Haematology·2018

Related Experiment Video

Updated: Apr 20, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959

Progress in acute myeloid leukemia.

Tapan M Kadia1, Farhad Ravandi1, Susan O'Brien1

  • 1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Clinical Lymphoma, Myeloma & Leukemia
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Recent advances in acute myeloid leukemia (AML) research, including genomics, have improved patient outcomes. Understanding AML

Keywords:
AMLReviewTargeted therapy

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.2K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.2K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Acute myeloid leukemia (AML) treatment has seen significant progress.
  • Genomic research has revitalized leukemia studies, improving outcomes.
  • AML is recognized as a heterogeneous disease, necessitating personalized treatment.

Purpose of the Study:

  • To provide a comprehensive review of current acute myeloid leukemia (AML) therapies.
  • To outline a strategic approach to managing distinct AML subtypes.
  • To highlight the impact of genomics on individualized AML treatment.

Main Methods:

  • Literature review of recent clinical research in AML.
  • Analysis of genomic data and its correlation with patient outcomes.
  • Synthesis of current therapeutic strategies based on patient-specific factors.

Main Results:

  • Improved outcomes in AML patients due to advancements in clinical research.
  • Personalized treatment strategies are effective for specific AML entities.
  • Genomic analysis is crucial for tailoring therapy based on age, cytogenetics, and mutations.

Conclusions:

  • Current AML therapy benefits from a deep understanding of disease heterogeneity.
  • Individualized treatment plans informed by genomics lead to better patient outcomes.
  • A roadmap for approaching distinct AML entities is essential for effective management.